Results 1 to 10 of about 39,266 (270)
Chronic Plaque Psoriasis [PDF]
South African Family Practice, 2006 Chronic plaque psoriasis, the most common form of psoriasis, is a papulosquamous disease defined by erythematous plaques with a silvery scale. The diagnosis usually is clinical, but occasionally a biopsy is necessary. Psoriasis affects 0.6 to 4.8 percent
K.M. Luba, D.L. Stulberg
doaj +5 more sources
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date [PDF]
Psoriasis: Targets and Therapy, 2018 Kristen M Beck, Isabelle M Sanchez, Eric J Yang, Wilson Liao Department of Dermatology, University of California San Francisco, San Francisco, CA, USA Abstract: Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the ...
Beck KM, Sanchez IM, Yang EJ, Liao W
doaj +2 more sources
Comparison of All-Cause Mortality in Generalized Pustular Psoriasis and Plaque Psoriasis: A Systematic Review and Meta-Analysis [PDF]
Dermatology and TherapyIntroduction Generalized pustular psoriasis (GPP) is a chronic, systemic neutrophilic inflammatory disease, associated with acute flares and life-threatening complications.
Bruce Strober +8 more
doaj +2 more sources
Indian Journal of DermatologyThe clinical efficacy of adalimumab in treating severe plaque psoriasis is significant, but many questions and uncertainties remain. To evaluate the efficacy of adalimumab in treating patients with severe plaque psoriasis and to explore potential ...
Jian-Qing Zhang +3 more
doaj +2 more sources
Deucravacitinib (Sotyktu™) for plaque psoriasis [PDF]
Trends in Pharmacological Sciences, 2023 The FDA has approved deucravacitinib (Sotyktu – BMS), an oral tyrosine kinase 2 (TYK2) inhibitor, for once-daily treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is the first selective TYK2 inhibitor to be approved in the US for any indication.
Granau, Agnete Marie +3 more
openaire +5 more sources
Myeloperoxidase Inhibition Ameliorates Plaque Psoriasis in Mice
Antioxidants, 2021 Plaque psoriasis is a common inflammatory condition of the skin characterized by red, flaking lesions. Current therapies for plaque psoriasis target many facets of the autoimmune response, but there is an incomplete understanding of how oxidative damage ...
Savannah D. Neu +5 more
doaj +1 more source
Secukinumab Therapy in Psoriasis Management
Berkala Ilmu Kesehatan Kulit dan Kelamin (Periodical of Dermatology and Venerology), 2022 Background : In recent years, use of biological therapy in psoriasis has increased as a result of advances in understanding the pathophysiology of psoriasis disease.
Ira Yunita, Sylvia Anggraeni
doaj +1 more source
A Case of Male Genital Psoriasis without Involvement of the Glans Penis
Case Reports in Dermatology, 2022 Genital psoriasis is a debilitating condition affecting approximately 49% of male psoriasis patients at least once during their lifetime. This condition often presents as generalized plaque psoriasis and features well-demarcated, erythematous plaques ...
Nicolas Zubrzycki, Liang Joo Leow
doaj +1 more source
How should we do in the selection and follow-up of systemic conventional treatments in psoriasis? [PDF]
Exploration of Musculoskeletal Diseases, 2023 There is an increasing need for appropriate effective treatment and long-term disease control in patients with psoriasis because of the decreased quality of life, increased physicosocial deficits and associated co-morbidities.
Sevgi Akarsu
doaj +1 more source
Vaccines, 2022 Clinical and epidemiologic data on pustular psoriasis are scarce. To investigate the phenotypes of pustular psoriasis and the patients’ characteristics observed in a real-life retrospective observational study.
Paolo Gisondi +2 more
doaj +1 more source